Pharma BD Deal Intelligence
Pfizer to acquire NextWave Pharmaceuticals for as much as $680-700 million, gaining the recently FDA-approved ADHD liquid formulation Quillivant XR.
Pfizer is paying up to $700M for NextWave to enter the Shire-dominated ADHD market with Quillivant XR, the first once-daily liquid methylphenidate; Pfizer's…
Quillivant XR launch positions Pfizer in a high-growth ADHD market with a differentiated once-daily liquid format aimed at pediatric patients who cannot…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Pfizer exercised option (initial $20M Q2 2012 option payment) to acquire NextWave with $255M closing payment plus up to $425M sales milestones. Acquired Quillivant XR, the first FDA-approved once-daily liquid ADHD medication (approved Sept 27 2012).
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / NextWave Pharmaceuticals, Inc. (this deal) | 2012 | $700M | 21 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2012 deals · Pfizer Inc. deals · Neurology deals